Amgen (AMGN) Q1 FY26 earnings call

Earnings call· Mar 2026 (Q1 FY26)· Health Care· Apr 30, 2026

Source: earnings call transcript

Amgen framed 2026 as a springboard year and Q1 delivered on that thesis: a cluster of newer growth drivers is outrunning the biosimilar erosion of Prolia/XGEVA, letting management raise full-year revenue and EPS guidance. Forward attention centers on the MariTide obesity program, an expanding late-stage pipeline, and early AI-driven R&D productivity gains, tempered by an escalating IRS transfer-pricing dispute.

You’re reading a preview. Opening the full call uses 1 concall credit.

Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.